Patients with moderate risk include those with a diagnosis of severe EBS, DDEB, and localized RDEB, while low risk has been established for patients with localized and intermediate EBS due to keratin and KLHL24 mutations. This evidence concerns the gene KLHL24 and epidermolysis bullosa simplex.